Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Sellas Life Sciences files $150M mixed securities shelf  17:11
04/16/21
04/16
17:11
04/16/21
17:11
SLS

Sellas Life Sciences

$7.50 /

-0.38 (-4.82%)

 
ShowHide Related Items >><<
SLS Sellas Life Sciences
$7.50 /

-0.38 (-4.82%)

SLS Sellas Life Sciences
$7.50 /

-0.38 (-4.82%)

02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
SLS Sellas Life Sciences
$7.50 /

-0.38 (-4.82%)

SLS Sellas Life Sciences
$7.50 /

-0.38 (-4.82%)

SLS Sellas Life Sciences
$7.50 /

-0.38 (-4.82%)

Conference/Events
Sellas Life Sciences participates in a conference call hosted by Maxim » 04:55
04/14/21
04/14
04:55
04/14/21
04:55
SLS

Sellas Life Sciences

$8.42 /

+0.23 (+2.81%)

Maxim hosts conference…

Maxim hosts conference call with CEO Stergiou on April 14.

ShowHide Related Items >><<
SLS Sellas Life Sciences
$8.42 /

+0.23 (+2.81%)

SLS Sellas Life Sciences
$8.42 /

+0.23 (+2.81%)

02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
SLS Sellas Life Sciences
$8.42 /

+0.23 (+2.81%)

SLS Sellas Life Sciences
$8.42 /

+0.23 (+2.81%)

SLS Sellas Life Sciences
$8.42 /

+0.23 (+2.81%)

Conference/Events
Sellas Life Sciences participates in a conference call hosted by Maxim » 10:31
04/12/21
04/12
10:31
04/12/21
10:31
SLS

Sellas Life Sciences

$8.45 /

-0.59 (-6.53%)

Maxim hosts conference…

Maxim hosts conference call with CEO Stergiou on April 14.

ShowHide Related Items >><<
SLS Sellas Life Sciences
$8.45 /

-0.59 (-6.53%)

SLS Sellas Life Sciences
$8.45 /

-0.59 (-6.53%)

02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
SLS Sellas Life Sciences
$8.45 /

-0.59 (-6.53%)

SLS Sellas Life Sciences
$8.45 /

-0.59 (-6.53%)

SLS Sellas Life Sciences
$8.45 /

-0.59 (-6.53%)

Over a month ago
Conference/Events
Maxim Group to hold a virtual conference » 04:55
03/18/21
03/18
04:55
03/18/21
04:55
CNSP

CNS Pharmaceuticals

$2.85 /

+0.18 (+6.74%)

, KTRA

Kintara Therapeutics

$2.14 /

-0.02 (-0.93%)

, PSTV

Plus Therapeutics

$2.85 /

+0.08 (+2.89%)

, TCON

Tracon Pharmaceuticals

$9.30 /

+0.2 (+2.20%)

, MDNA

Medicenna Therapeutics

$4.01 /

-0.01 (-0.25%)

, INO

Inovio

$10.53 /

+0.07 (+0.67%)

, ONCR

Oncorus

$16.33 /

-0.485 (-2.88%)

, GOVX

GeoVax Labs

$5.73 /

+0.39 (+7.30%)

, HTBX

Heat Biologics

$8.66 /

+0.3 (+3.59%)

, SLS

Sellas Life Sciences

$11.67 /

+1.25 (+12.00%)

, PLSE

Pulse Biosciences

$25.60 /

-0.4 (-1.54%)

, SRTS

Sensus Healthcare

$4.39 /

-0.02 (-0.45%)

, VERO

Venus Concept

$2.77 /

+0.18 (+6.95%)

, SOLY

Soliton

$16.86 /

-0.67 (-3.82%)

, CLXPF

Cybin

$0.00 /

+ (+0.00%)

, MMED

Midas Medici

$0.00 /

+ (+0.00%)

, CHFS

CHF Solutions

$6.19 /

-1.15 (-15.67%)

, ECOR

electroCore

$2.19 /

+0.095 (+4.53%)

, BIOL

Biolase

$1.01 /

+0.0553 (+5.79%)

, AEMD

Aethlon Medical

$2.25 /

-0.06 (-2.60%)

, ZSAN

Zosano Pharma

$1.47 /

+0.14 (+10.53%)

, NLSP

NLS Pharmaceutics

$4.51 /

+0.15 (+3.44%)

, CYTH

Cyclo Therapeutics

$12.80 /

+0.41 (+3.31%)

, MNPR

Monopar Therapeutics

$7.38 /

-0.11 (-1.47%)

Inaugural Emerging Growth…

Inaugural Emerging Growth Virtual Conference 2021 will be held on March 17-19.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

SOLY Soliton
$16.86 /

-0.67 (-3.82%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

PLSE Pulse Biosciences
$25.60 /

-0.4 (-1.54%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

ECOR electroCore
$2.19 /

+0.095 (+4.53%)

CYTH Cyclo Therapeutics
$12.80 /

+0.41 (+3.31%)

CNSP CNS Pharmaceuticals
$2.85 /

+0.18 (+6.74%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

CNSP CNS Pharmaceuticals
$2.85 /

+0.18 (+6.74%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

02/11/21
Fly Intel: Top five analyst initiations
02/11/21 H.C. Wainwright
Plus Therapeutics initiated with a Buy at H.C. Wainwright
01/25/21 Ladenburg
Plus Therapeutics initiated with a Buy at Ladenburg
10/16/20
Fly Intel: Top five analyst initiations
TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
09/17/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $7 from $4 at H.C. Wainwright
MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

12/17/20 Oppenheimer
Medicenna Therapeutics initiated with an Outperform at Oppenheimer
09/10/20 H.C. Wainwright
Medicenna Therapeutics initiated with a Buy at H.C. Wainwright
INO Inovio
$10.53 /

+0.07 (+0.67%)

03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
02/11/21 Oppenheimer
Inovio initiated with an Outperform at Oppenheimer
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

03/16/21
Fly Intel: Top five analyst initiations
03/16/21 Maxim
Oncorus initiated with a Buy at Maxim
11/11/20 Piper Sandler
Oncorus timelines remain on track after Q3 results, says Piper Sandler
10/27/20 Jefferies
Oncorus initiated with a Buy at Jefferies
GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
PLSE Pulse Biosciences
$25.60 /

-0.4 (-1.54%)

03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
02/04/21 H.C. Wainwright
Pulse Biosciences price target raised to $46 from $40 at H.C. Wainwright
01/26/21 H.C. Wainwright
Pulse Biosciences price target raised to $40 from $16 at H.C. Wainwright
SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

03/01/21 H.C. Wainwright
Sensus Healthcare price target raised to $6 from $4 at H.C. Wainwright
02/26/21 Northland
Northland upgrades Sensus Healthcare to Outperform after 'strong' Q4 report
02/26/21 Northland
Sensus Healthcare upgraded to Outperform from Market Perform at Northland
12/16/20 Northland
Sensus Healthcare downgraded to Market Perform on valuation at Northland
VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

12/29/20 BTIG
Venus Concept flying under the radar, says BTIG
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
11/16/20 Oppenheimer
Venus Concept upgraded to Outperform with $4 target at Oppenheimer
SOLY Soliton
$16.86 /

-0.67 (-3.82%)

03/08/21 Maxim
Soliton's multiple 2021 trials to expand its pipeline, says Maxim
02/08/21 Maxim
Soliton price target raised to $25 from $22 at Maxim
02/02/21 Cantor Fitzgerald
Soliton price target raised to $20 from $12 at Cantor Fitzgerald
07/15/20 Cantor Fitzgerald
Soliton initiated with an Overweight at Cantor Fitzgerald
CLXPF Cybin
$0.00 /

+ (+0.00%)

03/15/21 Canaccord
Cybin initiated with a Buy at Canaccord
01/14/21 Stifel
Cybin initiated with a Speculative Buy at Stifel
MMED Midas Medici
$0.00 /

+ (+0.00%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

10/21/20 Maxim
CHF Solutions price target lowered to $20 from $45 at Maxim
06/05/20 Maxim
CHF Solutions initiated with a Buy at Maxim
ECOR electroCore
$2.19 /

+0.095 (+4.53%)

10/22/20 Brookline
electroCore initiated with a Buy at Brookline
09/30/20
Fly Intel: Top five analyst initiationsNewPage
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

01/26/21 Maxim
Biolase price target raised to $2 at Maxim on 'strong' preliminary Q4 revenue
10/14/20 Maxim
Biolase initiated with a Buy at Maxim
04/09/20
Biolase supplying ventilators 'highly encouraging,' says Dougherty
AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Maxim
Aethlon Medical initiated with a Buy at Maxim
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

03/15/21 Maxim
Zosano Pharma price target raised to $2.50 from $1.50 at Maxim
10/22/20 BTIG
Zosano Pharma price target lowered to $2 from $7 at BTIG
10/02/20 H.C. Wainwright
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

03/12/21 Brookline
NLS Pharmaceutics initiated with a Buy at Brookline
03/03/21 Maxim
NLS Pharmaceutics initiated with a Buy at Maxim
CYTH Cyclo Therapeutics
$12.80 /

+0.41 (+3.31%)

02/10/21 Maxim
Cyclo Therapeutics price target raised to $25 from $12 at Maxim
12/17/20 Maxim
Cyclo Therapeutics initiated with a Buy at Maxim
MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

SOLY Soliton
$16.86 /

-0.67 (-3.82%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

ECOR electroCore
$2.19 /

+0.095 (+4.53%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

  • 17
    Mar
  • 12
    Feb
  • 29
    Jan
  • 21
    Jan
  • 23
    Dec
  • 22
    Dec
  • 02
    Oct
  • 25
    Sep
  • 01
    Sep
  • 26
    Jun
SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

Conference/Events
Maxim Group to hold a virtual conference » 09:48
03/17/21
03/17
09:48
03/17/21
09:48
CNSP

CNS Pharmaceuticals

$2.65 /

-0.02 (-0.75%)

, KTRA

Kintara Therapeutics

$2.08 /

-0.08 (-3.70%)

, PSTV

Plus Therapeutics

$2.75 /

-0.02 (-0.72%)

, TCON

Tracon Pharmaceuticals

$8.80 /

-0.3 (-3.30%)

, MDNA

Medicenna Therapeutics

$4.00 /

-0.02 (-0.50%)

, INO

Inovio

$10.33 /

-0.13 (-1.24%)

, ONCR

Oncorus

$16.50 /

-0.315 (-1.87%)

, GOVX

GeoVax Labs

$5.40 /

+0.06 (+1.12%)

, HTBX

Heat Biologics

$8.12 /

-0.24 (-2.87%)

, SLS

Sellas Life Sciences

$10.42 /

+ (+0.00%)

, PLSE

Pulse Biosciences

$26.20 /

+0.2 (+0.77%)

, SRTS

Sensus Healthcare

$4.40 /

-0.01 (-0.23%)

, VERO

Venus Concept

$2.43 /

-0.16 (-6.18%)

, SOLY

Soliton

$16.80 /

-0.73 (-4.16%)

, CLXPF

Cybin

$0.00 /

+ (+0.00%)

, MMED

Midas Medici

$0.00 /

+ (+0.00%)

, CHFS

CHF Solutions

$5.87 /

-1.47 (-20.03%)

, ECOR

electroCore

$2.07 /

-0.025 (-1.19%)

, BIOL

Biolase

$0.90 /

-0.0547 (-5.73%)

, AEMD

Aethlon Medical

$2.22 /

-0.09 (-3.90%)

, ZSAN

Zosano Pharma

$1.38 /

+0.05 (+3.76%)

, NLSP

NLS Pharmaceutics

$4.32 /

-0.04 (-0.92%)

, CYTH

Cyclo Therapeutics

$11.56 /

-0.83 (-6.70%)

, MNPR

Monopar Therapeutics

$7.40 /

-0.09 (-1.20%)

Inaugural Emerging Growth…

Inaugural Emerging Growth Virtual Conference 2021 will be held on March 17-19.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.38 /

+0.05 (+3.76%)

TCON Tracon Pharmaceuticals
$8.80 /

-0.3 (-3.30%)

SRTS Sensus Healthcare
$4.40 /

-0.01 (-0.23%)

SOLY Soliton
$16.80 /

-0.73 (-4.16%)

SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

PSTV Plus Therapeutics
$2.75 /

-0.02 (-0.72%)

PLSE Pulse Biosciences
$26.20 /

+0.2 (+0.77%)

ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

NLSP NLS Pharmaceutics
$4.32 /

-0.04 (-0.92%)

MNPR Monopar Therapeutics
$7.40 /

-0.09 (-1.20%)

MDNA Medicenna Therapeutics
$4.00 /

-0.02 (-0.50%)

KTRA Kintara Therapeutics
$2.08 /

-0.08 (-3.70%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

GOVX GeoVax Labs
$5.40 /

+0.06 (+1.12%)

ECOR electroCore
$2.07 /

-0.025 (-1.19%)

CYTH Cyclo Therapeutics
$11.56 /

-0.83 (-6.70%)

CNSP CNS Pharmaceuticals
$2.65 /

-0.02 (-0.75%)

CHFS CHF Solutions
$5.87 /

-1.47 (-20.03%)

BIOL Biolase
$0.90 /

-0.0547 (-5.73%)

AEMD Aethlon Medical
$2.22 /

-0.09 (-3.90%)

CNSP CNS Pharmaceuticals
$2.65 /

-0.02 (-0.75%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
KTRA Kintara Therapeutics
$2.08 /

-0.08 (-3.70%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
PSTV Plus Therapeutics
$2.75 /

-0.02 (-0.72%)

02/11/21
Fly Intel: Top five analyst initiations
02/11/21 H.C. Wainwright
Plus Therapeutics initiated with a Buy at H.C. Wainwright
01/25/21 Ladenburg
Plus Therapeutics initiated with a Buy at Ladenburg
10/16/20
Fly Intel: Top five analyst initiations
TCON Tracon Pharmaceuticals
$8.80 /

-0.3 (-3.30%)

02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
09/17/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $7 from $4 at H.C. Wainwright
MDNA Medicenna Therapeutics
$4.00 /

-0.02 (-0.50%)

12/17/20 Oppenheimer
Medicenna Therapeutics initiated with an Outperform at Oppenheimer
09/10/20 H.C. Wainwright
Medicenna Therapeutics initiated with a Buy at H.C. Wainwright
INO Inovio
$10.33 /

-0.13 (-1.24%)

03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
02/11/21 Oppenheimer
Inovio initiated with an Outperform at Oppenheimer
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

03/16/21
Fly Intel: Top five analyst initiations
03/16/21 Maxim
Oncorus initiated with a Buy at Maxim
11/11/20 Piper Sandler
Oncorus timelines remain on track after Q3 results, says Piper Sandler
10/27/20 Jefferies
Oncorus initiated with a Buy at Jefferies
GOVX GeoVax Labs
$5.40 /

+0.06 (+1.12%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
PLSE Pulse Biosciences
$26.20 /

+0.2 (+0.77%)

03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
02/04/21 H.C. Wainwright
Pulse Biosciences price target raised to $46 from $40 at H.C. Wainwright
01/26/21 H.C. Wainwright
Pulse Biosciences price target raised to $40 from $16 at H.C. Wainwright
SRTS Sensus Healthcare
$4.40 /

-0.01 (-0.23%)

03/01/21 H.C. Wainwright
Sensus Healthcare price target raised to $6 from $4 at H.C. Wainwright
02/26/21 Northland
Northland upgrades Sensus Healthcare to Outperform after 'strong' Q4 report
02/26/21 Northland
Sensus Healthcare upgraded to Outperform from Market Perform at Northland
12/16/20 Northland
Sensus Healthcare downgraded to Market Perform on valuation at Northland
VERO Venus Concept
$2.43 /

-0.16 (-6.18%)

12/29/20 BTIG
Venus Concept flying under the radar, says BTIG
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
11/16/20 Oppenheimer
Venus Concept upgraded to Outperform with $4 target at Oppenheimer
SOLY Soliton
$16.80 /

-0.73 (-4.16%)

03/08/21 Maxim
Soliton's multiple 2021 trials to expand its pipeline, says Maxim
02/08/21 Maxim
Soliton price target raised to $25 from $22 at Maxim
02/02/21 Cantor Fitzgerald
Soliton price target raised to $20 from $12 at Cantor Fitzgerald
07/15/20 Cantor Fitzgerald
Soliton initiated with an Overweight at Cantor Fitzgerald
CLXPF Cybin
$0.00 /

+ (+0.00%)

03/15/21 Canaccord
Cybin initiated with a Buy at Canaccord
01/14/21 Stifel
Cybin initiated with a Speculative Buy at Stifel
MMED Midas Medici
$0.00 /

+ (+0.00%)

CHFS CHF Solutions
$5.87 /

-1.47 (-20.03%)

10/21/20 Maxim
CHF Solutions price target lowered to $20 from $45 at Maxim
06/05/20 Maxim
CHF Solutions initiated with a Buy at Maxim
ECOR electroCore
$2.07 /

-0.025 (-1.19%)

10/22/20 Brookline
electroCore initiated with a Buy at Brookline
09/30/20
Fly Intel: Top five analyst initiationsNewPage
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
BIOL Biolase
$0.90 /

-0.0547 (-5.73%)

01/26/21 Maxim
Biolase price target raised to $2 at Maxim on 'strong' preliminary Q4 revenue
10/14/20 Maxim
Biolase initiated with a Buy at Maxim
04/09/20
Biolase supplying ventilators 'highly encouraging,' says Dougherty
AEMD Aethlon Medical
$2.22 /

-0.09 (-3.90%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Maxim
Aethlon Medical initiated with a Buy at Maxim
ZSAN Zosano Pharma
$1.38 /

+0.05 (+3.76%)

03/15/21 Maxim
Zosano Pharma price target raised to $2.50 from $1.50 at Maxim
10/22/20 BTIG
Zosano Pharma price target lowered to $2 from $7 at BTIG
10/02/20 H.C. Wainwright
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
NLSP NLS Pharmaceutics
$4.32 /

-0.04 (-0.92%)

03/12/21 Brookline
NLS Pharmaceutics initiated with a Buy at Brookline
03/03/21 Maxim
NLS Pharmaceutics initiated with a Buy at Maxim
CYTH Cyclo Therapeutics
$11.56 /

-0.83 (-6.70%)

02/10/21 Maxim
Cyclo Therapeutics price target raised to $25 from $12 at Maxim
12/17/20 Maxim
Cyclo Therapeutics initiated with a Buy at Maxim
MNPR Monopar Therapeutics
$7.40 /

-0.09 (-1.20%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
ZSAN Zosano Pharma
$1.38 /

+0.05 (+3.76%)

VERO Venus Concept
$2.43 /

-0.16 (-6.18%)

TCON Tracon Pharmaceuticals
$8.80 /

-0.3 (-3.30%)

SRTS Sensus Healthcare
$4.40 /

-0.01 (-0.23%)

SOLY Soliton
$16.80 /

-0.73 (-4.16%)

SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

PSTV Plus Therapeutics
$2.75 /

-0.02 (-0.72%)

ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

MNPR Monopar Therapeutics
$7.40 /

-0.09 (-1.20%)

MDNA Medicenna Therapeutics
$4.00 /

-0.02 (-0.50%)

KTRA Kintara Therapeutics
$2.08 /

-0.08 (-3.70%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

ECOR electroCore
$2.07 /

-0.025 (-1.19%)

CHFS CHF Solutions
$5.87 /

-1.47 (-20.03%)

BIOL Biolase
$0.90 /

-0.0547 (-5.73%)

AEMD Aethlon Medical
$2.22 /

-0.09 (-3.90%)

  • 17
    Mar
  • 12
    Feb
  • 29
    Jan
  • 21
    Jan
  • 23
    Dec
  • 22
    Dec
  • 02
    Oct
  • 25
    Sep
  • 01
    Sep
  • 26
    Jun
SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

ZSAN Zosano Pharma
$1.38 /

+0.05 (+3.76%)

VERO Venus Concept
$2.43 /

-0.16 (-6.18%)

ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

NLSP NLS Pharmaceutics
$4.32 /

-0.04 (-0.92%)

MDNA Medicenna Therapeutics
$4.00 /

-0.02 (-0.50%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

GOVX GeoVax Labs
$5.40 /

+0.06 (+1.12%)

TCON Tracon Pharmaceuticals
$8.80 /

-0.3 (-3.30%)

SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

Over a quarter ago
Recommendations
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim » 10:52
02/09/21
02/09
10:52
02/09/21
10:52
HTBX

Heat Biologics

$13.88 /

+5.49 (+65.44%)

, SLS

Sellas Life Sciences

$10.00 /

-0.09 (-0.89%)

, INO

Inovio

$13.69 /

-0.17 (-1.23%)

Heat Biologics (HTBX)…

Heat Biologics (HTBX) shares are up 60% this morning on positive interim survival data from the company's ongoing Phase 2 trial of HS-110 and nivolumab in both previously treated checkpoint inhibitor-naive and CI-treated advanced non-small cell lung cancer patients, Maxim analyst Jason McCarthy tells investors in a research note. One-year survival rate for Cohort A was 61.7%, which compares favorably to the 50.7% one-year survival rate noted with single-agent nivolumab therapy in the CheckMate 057 study, says the analyst. McCarthy adds that while a lot of focus has recently been placed on Heat's Covid vaccine candidate, the company's core oncology programs are continuing to make progress. With checkpoints, the cancer vaccine discussion "is back on the table," and "there is value to be unlocked," predicts McCarthy. He lists Heat Biologics, Sellas Life Sciences (SLS) and Inovio (INO) as cancer vaccine plays. McCarthy keeps a Buy rating on Heat Biologics with a $22 price target.

ShowHide Related Items >><<
SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
10/14/20 B. Riley
B. Riley sees 200% upside in 'value vaccine play' Heat Biologics
10/14/20 B. Riley
Heat Biologics initiated with a Buy at B. Riley Securities
SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
INO Inovio
$13.69 /

-0.17 (-1.23%)

01/08/21 Benchmark
Inovio price target lowered to $15 from $25 at Benchmark
12/28/20 Cantor Fitzgerald
Inovio may have viable third-generation vaccine, says Cantor Fitzgerald
12/28/20 H.C. Wainwright
Inovio Phase I Covid vaccine results 'very promising,' says H.C. Wainwright
12/24/20 Piper Sandler
Piper calls Inovio's COVID vaccine candidate 'an also-ran' after data published
SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

  • 21
    Jan
SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

Hot Stocks
Sellas Life Sciences announces 2020 highlights, 2021 milestones for NPS » 08:57
01/14/21
01/14
08:57
01/14/21
08:57
SLS

Sellas Life Sciences

$6.15 /

-0.23 (-3.61%)

Nelipepimut-S: In…

Nelipepimut-S: In December 2020, the Company announced positive final data with up to 6 months follow-up from the randomized Phase 2 trial of NPS in combination with granulocyte-macrophage colony-stimulating factor in women with ductal carcinoma in-situ of the breast who are HLA-A2+ or A3+ positive, express HER2 at IHC 1+, 2+, or 3+ levels, and are pre- or post-menopausal. This IST randomized patients to receive, prior to surgery, either GM-CSF followed by NPS two weeks later or GM-CSF alone. Preliminary data previously reported showed that treatment with even a single dose of NPS was capable of newly inducing NPS-specific cytotoxic T-lymphocytes in peripheral blood in DCIS patients. The updated data, based on a 6-month follow-up, demonstrate that CD8+ T-cell responses persist long-term post-NPS treatment, with treated patients retaining and modestly enhancing their antigen-specific immune response. When compared to baseline, i.e., prior to investigational agent administration, the relative frequency of NPS-specific CD8 CTLs as a percentage in peripheral blood at the 1-month and 6-month post-operative time-points increased in the NPS+GM-CSF group by 11- and 14-fold: 0.01+0.02% vs. 0.11+0.12% and 0.14+0.12%, respectively, while in the GM-CSF alone group the NPS-CLT% in peripheral blood increased by only 2.25- and 3.75-fold: 0.04+0.07% vs. 0.09+0.15% and 0.15+0.03%, respectively. For the NPS+GM-CSF group, the differences in absolute NPS-CTL% mean values between baseline and 1- or 6-months post-vaccination were statistically significant, with p-values of 0.039 and 0.0125, respectively. The relative change in NPS-CTL% mean values at 6 months post-vaccination was +1,300+450% for the NPS+GM-CSF group vs. 250+150% in the GM-CSF alone group, which was highly statistically significant in favor of the NPS+GM-CSF group: p=0.000094. These data were presented at the San Antonio Breast Cancer Symposium on December 11, 2020.

ShowHide Related Items >><<
SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

Hot Stocks
Sellas Life Sciences announces 2020 highlights, 2021 milestones for GPS » 08:56
01/14/21
01/14
08:56
01/14/21
08:56
SLS

Sellas Life Sciences

$6.15 /

-0.23 (-3.61%)

Galinpepimut-S: In…

Galinpepimut-S: In December 2020, the Company announced initial clinical data for GPS in combination with checkpoint inhibitors in two solid tumor indications in patients with advanced solid cancers who had exhausted their standard therapy options. In the Company's Phase 1/2 open-label study of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab in patients with selected advanced Wilms Tumor 1 positive cancers, the first set of evaluable patients diagnosed with 2nd or 3rd line WT1 relapsed or refractory metastatic ovarian cancer demonstrated a disease control rate of 87.5% with a median follow-up of 9.4 weeks and, at the first assessment time-point of 6 weeks post-therapy initiation, 100% of the patients were free of disease progression. In the Company's Phase 1 investigator-sponsored clinical trial of GPS in combination with the checkpoint inhibitor nivolumab in patients with macroscopic measurable deposits of malignant pleural mesothelioma who were either refractory to or relapsed after frontline tri-modality standard therapy, the first set of evaluable patients had a median progression free survival of at least 10 weeks since therapy initiation. Updated data on both studies are expected in first half of 2021. In December 2020, the Company announced that it had entered into an exclusive license agreement with 3D Medicines Inc., a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development and commercialization of GPS, as well as the Company's next generation heptavalent immunotherapeutic GPS+, which is at preclinical stage, across all therapeutic and diagnostic uses in the Greater China territory. SELLAS retains sole rights to GPS and GPS+ outside of the Greater China area. Potential payments to SELLAS under the agreement in licensing fees and milestone payments, not including potential future royalties, could total $202 million, including an upfront license fee of $7.5 million paid in December 2020. In September 2020, SELLAS announced that it received approval of its Investigational Medicinal Product Dossier from the French regulatory authority, Agence Nationale de Securite du Medicament et des Produits de Sante, to advance in France its pivotal Phase 3 REGAL study of GPS in AML CR2 patients. The Company has subsequently received IMPD approval from the German health authorities and expects approvals from additional European health authorities in early 2021 which will allow SELLAS to expand AML patient enrollment for the pivotal Phase 3 REGAL study of GPS in Europe. In the spring of 2020, the Company established an Independent Data Monitoring Committee of leading clinical and biostatistics experts to review and evaluate patient safety and efficacy data for the Phase 3 REGAL trial and also appointed a Steering Committee of leading AML experts for the study. The DMC is responsible for reviewing and evaluating patient safety and efficacy data and will review study data at regular intervals in order to ensure the safety of all patients enrolled in the study. The Steering Committee will provide scientific oversight and guidance of the practical aspects of the study and will make recommendations regarding the monitoring of the study in consultation with the DMC. In February 2020, the Company announced positive final follow-up data from its Phase 2 clinical trial of GPS in AML CR2 patients. The final data showed a median overall survival of 21.0 months, at a median follow-up of 30.8 months, in patients receiving GPS therapy compared to 5.4 months in the AML CR2 patients treated with best standard care, a statistically significant difference. Final analysis showed that GPS therapy continued to be well-tolerated throughout the study. The Company previously reported initial data from this Phase 1/2 study at a median follow-up of 19.3 months, showing median OS in GPS-treated patients of 16.3 months vs. 5.4 months in a patient cohort contemporaneously treated with best standard therapy.

ShowHide Related Items >><<
SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

Hot Stocks
Sellas Life Sciences reports $35.3M in cash, cash equivalents as of Dec. 31 » 08:54
01/14/21
01/14
08:54
01/14/21
08:54
SLS

Sellas Life Sciences

$6.15 /

-0.23 (-3.61%)

"2020 was a…

"2020 was a transformative year for SELLAS as we commenced the pivotal Phase 3 REGAL study of GPS in patients with AML who have achieved complete remission after second-line anti-leukemic therapy in the United States and Europe and also announced important clinical data in the same patient cohort from our completed Phase 2 study showing a median overall survival of 21 months vs. 5.4 months in favor of patients who received GPS, with a p-value of 0.02. We are also intrigued by the recently announced initial data from two studies of GPS in combination with checkpoint inhibitors in ovarian and malignant pleural mesothelioma indications, and we look forward to providing further data from these studies in the first half of 2021. We were also pleased to present last month at the 2020 San Antonio Breast Cancer Symposium positive final data with up to 6 months follow-up from the randomized Phase 2 trial of nelipepimut-S in combination with granulocyte-macrophage colony-stimulating factor in women with ductal carcinoma in-situ of the breast showing immune stimulation augmented by +1,300% at 6-months post-NPS treatment and a statistically significant difference of duration of immune response of NPS vs. control with a p-value of 0.000094," stated Angelos Stergiou, MD, ScD h.c, President and CEO of SELLAS. "Additionally, we began preparations for the commercialization of GPS, assuming we achieve positive data from the REGAL study, with a collaboration with 3D Medicines Inc. for the development and commercialization of GPS in Greater China which we announced at the end of 2020. This licensing transaction with 3D Medicines for GPS has been ranked by PharmaCube, a leading Chinese database, as one of the top ten life sciences licensing transactions in China in 2020 in terms of the total financial consideration. Importantly, we strengthened our balance sheet in 2020 with gross proceeds of approximately $47.9 million from the sale of securities, exercise of warrants, and the upfront payment from 3D Medicines and we ended the year with approximately $35.3 million in cash and cash equivalents. The proceeds from these transactions will significantly support the GPS clinical programs."

ShowHide Related Items >><<
SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

SLS Sellas Life Sciences
$6.15 /

-0.23 (-3.61%)

Options
new option listings and one option delisting on December 23rd » 08:30
12/23/20
12/23
08:30
12/23/20
08:30
CAAP

Corporacion America Airport

$3.84 /

-0.135 (-3.40%)

, CNXC

Concentrix

$97.72 /

-1.23 (-1.24%)

, DAC

Danaos

$19.91 /

-0.68 (-3.30%)

, DADA

Dada Nexus

$36.99 /

-0.87 (-2.30%)

, DMAC

DiaMedica Therapeutics

$8.27 /

+0.14 (+1.72%)

, GIK

GigCapital3

$12.06 /

-0.38 (-3.05%)

, GIX

GigCapital2

$10.45 /

-0.025 (-0.24%)

, IPOE

Social Capital Hedosophia Holdings Corp. V

$11.60 /

+0.19 (+1.67%)

, IPOF

Social Capital Hedosophia Holdings Corp. VI

$11.78 /

+0.13 (+1.12%)

, IPV

InterPrivate Acquisition Corp

$18.64 /

+3.74 (+25.10%)

, LGVW

Longview Acquisition Corp.

$17.19 /

+2.3 (+15.45%)

, NGA

Northern Genesis Acquisition

$15.69 /

+0.73 (+4.88%)

, QELL

Qell Acquisition

$12.48 /

+0.26 (+2.13%)

, SLS

Sellas Life Sciences

$7.06 /

+0.01 (+0.14%)

, TPGY

TPG Pace Beneficial Finance

$29.07 /

+3.47 (+13.55%)

, VGAC

VG Acquisition

$11.88 /

+0.4 (+3.48%)

, YMTX

Yumanity Therapeutics

$0.00 /

+ (+0.00%)

, PTI

Merged into YMTX

$1.10 /

-0.055 (-4.76%)

New option listings for…

New option listings for December 23rd include Corporacion America Airports SA (CAAP), Collective Growth Corporation (Class A Stock) (CGRO), Concentrix Corporation (CNXC), Danaos (DAC), Dada Nexus Ltd (ADS) (DADA), DiaMedica Therapeutics Inc (DMAC), GigCapital3 Inc (GIK), GigCapital2 Inc (GIX), Social Capital Hedosophia Holdings Corp V (IPOE), Social Capital Hedosophia Holdings Corp VI (Class A Stock) (IPOF), InterPrivate Acquisition Corp (IPV), Longview Acquisition Corp (Class A Stock) (LGVW), Northern Genesis Acquisition Corp (NGA), Qell Acquisition Corporation (Class A Stock) (QELL), Main Sector Rotation ETF (SECT), Sellas Life Sciences (SLS), Star Peak Energy Transition Corp (Class A Stock) (STPK), TPG Pace Beneficial Finance Corp (Class A Stock) (TPGY), VG Acquisition Corp (Class A Stock) (VGAC), WisdomTree Emerging Mkts exState Owned Enterprises Fund (XSOE), and Yumanity Therapeutics Inc (YMTX). Option delistings effective December 23rd include Proteostasis Therapeutics Inc (PTI).

ShowHide Related Items >><<
TPGY TPG Pace Beneficial Finance
$29.07 /

+3.47 (+13.55%)

SLS Sellas Life Sciences
$7.06 /

+0.01 (+0.14%)

PTI Merged into YMTX
$1.10 /

-0.055 (-4.76%)

NGA Northern Genesis Acquisition
$15.69 /

+0.73 (+4.88%)

LGVW Longview Acquisition Corp.
$17.19 /

+2.3 (+15.45%)

IPV InterPrivate Acquisition Corp
$18.64 /

+3.74 (+25.10%)

GIX GigCapital2
$10.45 /

-0.025 (-0.24%)

GIK GigCapital3
$12.06 /

-0.38 (-3.05%)

DMAC DiaMedica Therapeutics
$8.27 /

+0.14 (+1.72%)

DADA Dada Nexus
$36.99 /

-0.87 (-2.30%)

DAC Danaos
$19.91 /

-0.68 (-3.30%)

CNXC Concentrix
$97.72 /

-1.23 (-1.24%)

CAAP Corporacion America Airport
$3.84 /

-0.135 (-3.40%)

CAAP Corporacion America Airport
$3.84 /

-0.135 (-3.40%)

04/08/20 Goldman Sachs
Corporacion America Airport downgraded to Neutral from Buy at Goldman Sachs
CNXC Concentrix
$97.72 /

-1.23 (-1.24%)

12/08/20 Stifel
Synnex downgraded to Hold from Buy at Stifel
12/07/20 BofA
Concentrix initiated with a Buy at BofA
12/07/20 BofA
Concentrix initiated with a Buy at BofA
DAC Danaos
$19.91 /

-0.68 (-3.30%)

12/09/20 Jefferies
Danaos price target raised to $18 from $13 at Jefferies
09/28/20 Citi
Danaos price target raised to $6.25 from $4.75 at Citi
DADA Dada Nexus
$36.99 /

-0.87 (-2.30%)

12/08/20
Fly Intel: Top five analyst downgrades
12/08/20 Morgan Stanley
Dada Nexus downgraded to Equal Weight on competition risk at Morgan Stanley
12/08/20 Morgan Stanley
Dada Nexus downgraded to Equal Weight from Overweight at Morgan Stanley
11/11/20
Fly Intel: Top five analyst upgrades
DMAC DiaMedica Therapeutics
$8.27 /

+0.14 (+1.72%)

10/30/20 Guggenheim
DiaMedica Therapeutics initiated with a Buy at Guggenheim
07/08/20 Maxim
DiaMedica Therapeutics initiated with a Buy at Maxim
05/15/20 Lake Street
DiaMedica Therapeutics price target raised to $14 from $9 at Lake Street
GIK GigCapital3
$12.06 /

-0.38 (-3.05%)

GIX GigCapital2
$10.45 /

-0.025 (-0.24%)

IPOE Social Capital Hedosophia Holdings Corp. V
$11.60 /

+0.19 (+1.67%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$11.78 /

+0.13 (+1.12%)

IPV InterPrivate Acquisition Corp
$18.64 /

+3.74 (+25.10%)

LGVW Longview Acquisition Corp.
$17.19 /

+2.3 (+15.45%)

NGA Northern Genesis Acquisition
$15.69 /

+0.73 (+4.88%)

QELL Qell Acquisition
$12.48 /

+0.26 (+2.13%)

SLS Sellas Life Sciences
$7.06 /

+0.01 (+0.14%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
TPGY TPG Pace Beneficial Finance
$29.07 /

+3.47 (+13.55%)

VGAC VG Acquisition
$11.88 /

+0.4 (+3.48%)

YMTX Yumanity Therapeutics
$0.00 /

+ (+0.00%)

PTI Merged into YMTX
$1.10 /

-0.055 (-4.76%)

10/14/20 Piper Sandler
Piper upgrades Proteostasis ahead of reverse merger with Yumanity
10/14/20 Piper Sandler
Proteostasis upgraded to Overweight from Neutral at Piper Sandler
08/24/20 Piper Sandler
Proteostasis downgraded to Neutral from Overweight at Piper Sandler
02/24/20 Piper Sandler
Proteostasis' Phase III CHOICES trial fully enrolled, says Piper Sandler
SLS Sellas Life Sciences
$7.06 /

+0.01 (+0.14%)

PTI Merged into YMTX
$1.10 /

-0.055 (-4.76%)

DADA Dada Nexus
$36.99 /

-0.87 (-2.30%)

CAAP Corporacion America Airport
$3.84 /

-0.135 (-3.40%)

  • 03
    Dec
  • 24
    Nov
  • 18
    Aug
  • 05
    Jun
  • 11
    Feb
SLS Sellas Life Sciences
$7.06 /

+0.01 (+0.14%)

GIX GigCapital2
$10.45 /

-0.025 (-0.24%)

GIK GigCapital3
$12.06 /

-0.38 (-3.05%)

QELL Qell Acquisition
$12.48 /

+0.26 (+2.13%)

NGA Northern Genesis Acquisition
$15.69 /

+0.73 (+4.88%)

LGVW Longview Acquisition Corp.
$17.19 /

+2.3 (+15.45%)

IPOE Social Capital Hedosophia Holdings Corp. V
$11.60 /

+0.19 (+1.67%)

DADA Dada Nexus
$36.99 /

-0.87 (-2.30%)

DAC Danaos
$19.91 /

-0.68 (-3.30%)

DAC Danaos
$19.91 /

-0.68 (-3.30%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.